Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport

• Published in: Journal of Neural Transmission 2015-03, Vol.122 (3), p.427-431
• Main Authors: Kollewe, Katja, Mohammadi, Bahram, Köhler, Steffen, Pickenbrock, Heidrun, Dengler, Reinhard, Dressler, Dirk
• Format: Article
• Language: English
• Subjects: Acetylcholine Release Inhibitors - therapeutic use; Adult; Aged; Aged, 80 and over; Blepharospasm - drug therapy; Botulinum Toxins, Type A - therapeutic use; Dose-Response Relationship, Drug; Female; Humans; Longitudinal Studies; Male; Medicine; Medicine & Public Health; Middle Aged; Neurology; Neurology and Preclinical Neurological Studies - Original Article; Neurosciences; Psychiatry; Retrospective Studies; Treatment Outcome
• ISSN: 0300-9564; 1435-1463
• DOI: 10.1007/s00702-014-1278-z

Botulinum toxin (BT) therapy is the treatment of choice for blepharospasm (BPS). Currently available BT type A drugs include Botox ® , Dysport ® and Xeomin ® . Until now, there are few long-term studies on BT therapy for BPS. This is the first long-term study comparing all three major BT drugs. We collected treatment, efficacy and adverse effect data on BPS patients treated with either Botox ® , Dysport ® or Xeomin ® for at least eight consecutive treatments. Two hundred and eighty-eight patients (208 females, 80 males, age 62 ± 12 years) were included in this study. The treatment time was 11.2 ± 4.1 years covering 10,701 injection series. Doses were 47 ± 10 MU for Botox ® , 120 ± 35 MU for Dysport ® and 62 ± 11 MU for Xeomin ® (Botox ® dose vs Xeomin ® dose: p